Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus.
OBJECTIVE
To evaluate the relationship between laboratory markers of HIV, AIDS-defining events, study discontinuation, and summary scores from the MOS-HIV Health Survey.


METHODS
Secondary analysis of data from a clinical trial of antiretroviral therapies in advanced HIV-infected patients (N = 940). Clinical and health-related quality-of-life data were collected over 48 weeks. Linear regression, logistic regression and survival analyses were performed to evaluate the relationships between MOS-HIV summary scores, clinical events, and laboratory markers.


RESULTS
Each point increase in PHS resulted in a 3.0% decrease in the likelihood of developing an AIDS-defining event (p < .05) and a 2.7% decrease in likelihood of study discontinuation (p < .05). MHS did not significantly predict clinical events, but did predict study discontinuation (p < .05). From the linear regression analyses, the change in CD4 counts was a significant predictor of the change in MHS (p < .01).


CONCLUSIONS
The MOS-HIV summary scores predict clinical events and study discontinuation in advanced HIV-infected patients.
Chan
K S
KS
Center for Health Outcomes Research, MEDTAP International, Bethesda, MD 20814, USA. Chan@Medtap.com
Revicki
D A
DA
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D015415:Biomarkers; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000401:mortality / Q000523:psychology; D006306:Health Surveys; D006801:Humans; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D016019:Survival Analysis
D000998:Antiviral Agents; D015415:Biomarkers